2024-09-12
On September 10th, the 2024 Shenzhen Biomedical Industry Investment and Promotion Conference was successfully held. BOCG’s portfolio companies, Boan Biotech and Ribo Life Science, participated in the signing ceremony as partners, announcing their intent to establish a presence in Shenzhen. Frank Yang, Founding Partner and CEO of BOCG, was interviewed by several media outlets, sharing his insights on Shenzhen’s unique advantages and prospects for developing the biomedical industry as an innovative city in the Greater Bay Area.
More than 300 representatives from pharmaceutical companies, investment institutions, research organizations, industrial parks, and industry experts from across the country were invited to attend the conference.
Prof. Nieng Yan, member of the Chinese Academy of Sciences, Founding President of Shenzhen Medical Academy of Research & Translation and director of the Shenzhen Bay Laboratory, shared insights on the development of Shenzhen’s biomedical industry and its comprehensive support policies. She extended an invitation to global scientists, stating, “We welcome all of you to join us in building Shenzhen into a biomedical hub and the ‘Eastern Greater Bay Area’ for life sciences.”
During the signing ceremony, BOCG’s portfolio companies, Shandong Boan Biotech Co., Ltd., Suzhou Ribo Life Science Co., Ltd., and 18 other Biotech companies signed cooperation agreements with related government bodies. They announced plans to establish a presence in Shenzhen, aiming to leverage the city’s competitive advantages including a innovative and a world-class business environment and the inherent advantages of the cooperation between Shenzhen and Hong Kong. In recent years, biomedical industry has been one of the most innovative and promoted sectors by Shenzhen government among its “20+8” strategic emerging industry clusters. From 2014 to 2023, the output value of Shenzhen’s biopharmaceutical manufacturing industry grew from RMB 20.3 billion to RMB 53.0 billion, with a compound annual growth rate of 11.3%, showing a steady growth trend.
Frank Yang, Founding Partner and CEO of BOCG, was interviewed by media outlets such as Greater Bay News and Shenzhen TV. BOCG has successively invested in outstanding innovative companies such as HighTide Therapeutics, Innorna, and Signet Therapeutics in Shenzhen. BOCG continues to increase its investment footprint in Shenzhen, actively collaborating with pharmaceutical companies and research institutions, leveraging innovative resources and talents from Europe and the U.S and investing in innovative start-ups in the Greater Bay Area.
